Quick Answer
SUTRO BIOPHARMA, INC. reported Total Revenue of $102.48 million for fiscal year 2025.
SUTRO BIOPHARMA, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $102.48M +65.2% |
$62.04M -59.6% |
$153.73M +126.8% |
$67.77M +9.5% |
$61.88M +44.8% |
$42.72M -0.0% |
| Revenue (ASC 606) | $102.48M +65.2% |
$62.04M -59.6% |
$153.73M +126.8% |
$67.77M +9.5% |
$61.88M +44.8% |
$42.72M -0.0% |
| Net Income | -$191.09M +16.0% |
-$227.46M -113.0% |
-$106.79M +10.4% |
-$119.20M -12.9% |
-$105.54M -228.5% |
-$32.13M +73.0% |
| Diluted EPS | -$22.49 +23.5% |
-$29.40 -1551.7% |
-$1.78 +24.3% |
-$2.35 -2.6% |
-$2.29 -131.3% |
-$0.99 |
| Total Assets | $173.83M -55.1% |
$387.21M -17.7% |
$470.74M +15.7% |
$406.94M +19.2% |
$341.41M -13.4% |
$394.11M +152.0% |
| Cash and Equivalents | $58.13M -69.5% |
$190.30M +174.7% |
$69.27M +46.6% |
$47.25M +55.4% |
$30.41M -85.2% |
$206.15M +4056.3% |
| Long-Term Debt | — | — | $0.00 -100.0% |
$3.77M -76.0% |
$15.74M -35.9% |
$24.55M +176.5% |
| Stockholders Equity | -$132.45M -397.0% |
$44.60M -70.2% |
$149.65M -31.1% |
$217.05M -14.1% |
$252.56M -23.9% |
$332.05M +239.6% |
| R&D Expense | $166.42M -34.0% |
$252.04M +39.7% |
$180.43M +31.5% |
$137.17M +31.4% |
$104.40M +35.7% |
$76.96M +17.3% |
| Operating Income | -$158.37M +33.6% |
-$238.45M -167.1% |
-$89.28M +30.8% |
-$128.94M -30.9% |
-$98.52M -38.7% |
-$71.06M -28.1% |
| Shares Outstanding | 8.58M +3.3% |
8.31M -86.4% |
61.01M +6.1% |
57.50M +24.1% |
46.33M +1.3% |
45.75M +98.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $9.69M | +13.8% | -84.8% |
| Revenue (ASC 606) | September 30, 2025 | $9.69M | +13.8% | -84.8% |
| Net Income | September 30, 2025 | -$56.86M | -16.5% | -394.5% |
| Diluted EPS | September 30, 2025 | -$0.67 | -13.6% | -378.6% |
| Total Assets | September 30, 2025 | $209.66M | -53.6% | -20.1% |
| Cash and Equivalents | September 30, 2025 | $65.93M | -62.2% | +3.0% |
| Long-Term Debt | December 31, 2022 | $3.77M | -76.0% | -44.4% |
| Stockholders Equity | September 30, 2025 | -$87.27M | -178.5% | -171.8% |
| R&D Expense | September 30, 2025 | $39.85M | -35.8% | +4.0% |
| Operating Income | September 30, 2025 | -$48.46M | +28.7% | -1348.7% |
| Shares Outstanding | September 30, 2025 | 85.10M | +3.3% | +0.5% |
- SUTRO BIOPHARMA, INC. reported Total Revenue of $102.48 million for fiscal year 2025.
- SUTRO BIOPHARMA, INC. showed an increase of +65.2% in Total Revenue compared to the prior fiscal year.
- SUTRO BIOPHARMA, INC. reported Revenue (ASC 606) of $102.48 million for fiscal year 2025.
- SUTRO BIOPHARMA, INC. showed an increase of +65.2% in Revenue (ASC 606) compared to the prior fiscal year.
- SUTRO BIOPHARMA, INC. reported Net Income of -$191.09 million for fiscal year 2025.
- SUTRO BIOPHARMA, INC. showed an increase of +16.0% in Net Income compared to the prior fiscal year.
- SUTRO BIOPHARMA, INC. reported Diluted EPS of $22.49 per share (loss) for fiscal year 2025.
- SUTRO BIOPHARMA, INC. showed an increase of +23.5% in Diluted EPS compared to the prior fiscal year.
- SUTRO BIOPHARMA, INC. reported Total Assets of $173.83 million for fiscal year 2025.
- SUTRO BIOPHARMA, INC. showed a decrease of -55.1% in Total Assets compared to the prior fiscal year.
- SUTRO BIOPHARMA, INC. reported Cash and Equivalents of $58.13 million for fiscal year 2025.
- SUTRO BIOPHARMA, INC. showed a decrease of -69.5% in Cash and Equivalents compared to the prior fiscal year.
- SUTRO BIOPHARMA, INC. reported Long-Term Debt of $0.00 for fiscal year 2023.
- SUTRO BIOPHARMA, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- SUTRO BIOPHARMA, INC. reported Stockholders Equity of -$132.45 million for fiscal year 2025.
- SUTRO BIOPHARMA, INC. showed a decrease of -397.0% in Stockholders Equity compared to the prior fiscal year.
- SUTRO BIOPHARMA, INC. reported R&D Expense of $166.42 million for fiscal year 2025.
- SUTRO BIOPHARMA, INC. showed a decrease of -34.0% in R&D Expense compared to the prior fiscal year.
- SUTRO BIOPHARMA, INC. reported Operating Income of -$158.37 million for fiscal year 2025.
- SUTRO BIOPHARMA, INC. showed an increase of +33.6% in Operating Income compared to the prior fiscal year.
- SUTRO BIOPHARMA, INC. reported Shares Outstanding of 8.58 million shares for fiscal year 2025.
- SUTRO BIOPHARMA, INC. showed an increase of +3.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: